View Older Stories View More Recent Stories

Dec 18, 2018 05:03PM Ligand Pharma (LGND) Introduces FY19 Financial Outlook, Raises FY18 Financial Guidance
Dec 18, 2018 05:00PM Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Dec 17, 2018 04:05PM Ligand Pharma (LGND) Buys Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Dec 17, 2018 04:01PM Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Dec 17, 2018 09:00AM Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma
Nov 21, 2018 09:01AM Ligand Pharma (LGND) Announces OmniAb Partnership with iMetabolic Biopharma Corporation
Nov 21, 2018 09:00AM Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Nov 13, 2018 09:00AM Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo
Nov 8, 2018 08:00AM Ligand Reports Third Quarter 2018 Financial Results
Nov 2, 2018 09:00AM Ligand to Participate in Stephens NY Investment Conference
Oct 15, 2018 09:00AM Ligand to Report Third Quarter 2018 Results on November 8th
Oct 10, 2018 09:00AM Ligand Announces the Close of its Acquisition of Vernalis
Aug 29, 2018 09:00AM Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Aug 9, 2018 08:14AM Ligand Pharma (LGND) Offers to Acquire Vernalis for $43 Million
Aug 9, 2018 08:08AM Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Aug 6, 2018 04:01PM Ligand Reports Second Quarter 2018 Financial Results
Jul 9, 2018 09:00AM Ligand to Report Second Quarter 2018 Results on August 6th
Jun 27, 2018 09:03AM Ligand Pharma (LGND) Updates 2018 Revenue Guidance; Secures $47M Payment from WuXi Biologics for Expansion of Worldwide OmniAb Platform License Agreement
Jun 27, 2018 09:00AM Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
May 11, 2018 09:00AM Ligand to Participate in Upcoming Investor Conferences
May 8, 2018 04:01PM Ligand Reports First Quarter 2018 Financial Results
Apr 24, 2018 09:00AM Ligand to Report First Quarter 2018 Results on May 8th
Mar 30, 2018 09:00AM Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Mar 6, 2018 04:01PM Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Mar 5, 2018 04:01PM Ligand to Participate in Two Upcoming Investor Conferences
Feb 21, 2018 04:01PM Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Feb 5, 2018 04:01PM Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
Jan 22, 2018 09:02AM Ligand Pharma (LGND) Reports License Agreement with Ferring Pharmaceuticals
Jan 22, 2018 09:00AM Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals
Jan 18, 2018 04:01PM Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
Jan 11, 2018 09:00AM Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
Jan 3, 2018 09:02AM Ligand Pharma (LGND) Secures $6M Payments from OmniAb Partner Out-Licenses Antibody Projects
Jan 3, 2018 09:00AM Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
Nov 14, 2017 05:27PM Ligand Pharma (LGND) Offers Highlights from Today's Analyst Day Event
Nov 14, 2017 05:25PM Ligand Provides Highlights from Today’s Analyst Day Event
Nov 9, 2017 04:01PM Ligand Reports Third Quarter 2017 Financial Results
Nov 6, 2017 09:00AM Reminder: Ligand to Host Analyst Day on November 14th in New York City
Nov 2, 2017 09:15AM Ligand to Participate in the Stephens Fall Investment Conference
Oct 24, 2017 04:01PM Ligand to Report Third Quarter 2017 Results on November 9th
Oct 4, 2017 04:06PM Ligand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus Milestones
Oct 4, 2017 04:05PM Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
Sep 25, 2017 09:00AM Ligand to Host Analyst Day on November 14th in New York City
Sep 1, 2017 09:00AM Ligand to Participate in Two Upcoming Investor Conferences
Aug 21, 2017 09:02AM Ligand Pharma (LGND) Names Dr. Nancy Gray to Board
Aug 21, 2017 09:00AM Ligand Appoints Dr. Nancy Gray to its Board of Directors
Aug 18, 2017 09:03AM Ligand Pharma (LGND) Receive $2M from WuXi Biologics for Licensing anti-PD-1 Antibody Discovered Using the OmniAb Technology
Aug 18, 2017 09:00AM Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
Aug 7, 2017 04:01PM Ligand Reports Second Quarter 2017 Financial Results
Jul 20, 2017 04:01PM Ligand to Report Second Quarter 2017 Results on August 7th
Jul 17, 2017 09:03AM Ligand Pharma (LGND) Enters Pact with Amgen for Rights to Use Captisol in Formulation of AMG 330
View More Recent Stories View Older Stories